LXRX - Lexicon Pharmaceuticals Putting The Pieces Together But Much Is Left To Do
2024-01-26 10:31:26 ET
Summary
- Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers.
- Multiple studies support the cost efficacy of Inpefa for heart failure, and this could become a more significant competitive differentiator for insurers if real-world experience follows accordingly.
- Lexicon also has other opportunities in its pipeline, including the development of LX9211 for diabetic peripheral neuropathic pain and a possible path to approval for sotagliflozin for Type 1 diabetes.
- Lexicon's track record is not the best, and while there is significant upside if Lexicon successfully commercializes Inpefa, failure is very much a possible outcome.
It's been an interesting few months for Lexicon Pharmaceuticals (LXRX) since I last wrote about this small, commercialization-stage biotech. While the share price fell below $1 on a few occasions, increased optimism around the company's efforts to get its lead drug Inpefa onto formularies and see meaningful growth in prescriptions has helped the stock gain back enough ground to be more or less flat with where it was at the time of that last article....
Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do